Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting Mar 21, 2022
Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022 Mar 18, 2022
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea Mar 17, 2022
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 Mar 09, 2022
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 Mar 03, 2022
